Puma Biotechnology Inc reports results for the quarter ended March 31 - Earnings Summary

• Puma Biotechnology Inc PBYI.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of three analysts for the quarter was for a loss of 2 cents per share. Wall Street expected results to range from -3 cents to -1 cents per share.

• Revenue rose 5% to $46.00 million from a year ago; analysts expected $44.55 million.

• Puma Biotechnology Inc's reported EPS for the quarter was 6 cents​.

• The company reported quarterly net income of $3 million.

• Puma Biotechnology Inc shares had risen by 1.0% this quarter and lost 2.0% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "hold"

• Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.50

This summary was machine generated from LSEG data May 8 at 10:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)